Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Monoclonals..
Bamlanivimab/etesevimab
Bebtelovimab
Casirivimab/imdevimab
Sotrovimab
Tixagevimab/cilgavimab
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Vitamin A
Vitamin C
Vitamin D
Zinc
Other
Feedback
Home
Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes
Feedback
12 nitazoxanide COVID-19 controlled studies, 9 RCTs
33% improvement for early treatment, RR 0.67 [0.25-1.78]
c19nitazoxanide.com Aug 2022
Home
COVID-19 treatment studies for Nitazoxanide
COVID-19 treatment studies for Nitazoxanide
C19 studies: Nitazoxanide
Nitazoxanide
Select treatment
Select treatment
Treatments
Treatments
Antiandrogens
(meta)
Melatonin
(meta)
Aspirin
(meta)
Metformin
(meta)
Bamlaniv../e..
(meta)
Molnupiravir
(meta)
Bebtelovimab
(meta)
N-acetylcys..
(meta)
Bromhexine
(meta)
Nigella Sativa
(meta)
Budesonide
(meta)
Nitazoxanide
(meta)
Cannabidiol
(meta)
Nitric Oxide
(meta)
Casirivimab/i..
(meta)
Paxlovid
(meta)
Colchicine
(meta)
Peg.. Lambda
(meta)
Conv. Plasma
(meta)
Povidone-Iod..
(meta)
Curcumin
(meta)
Probiotics
(meta)
Diet
(meta)
Proxalutamide
(meta)
Ensitrelvir
(meta)
Quercetin
(meta)
Ensovibep
(meta)
Remdesivir
(meta)
Exercise
(meta)
Sleep
(meta)
Famotidine
(meta)
Sotrovimab
(meta)
Favipiravir
(meta)
Tixagev../c..
(meta)
Fluvoxamine
(meta)
Vitamin A
(meta)
Hydroxychlor..
(meta)
Vitamin C
(meta)
Iota-carragee..
(meta)
Vitamin D
(meta)
Ivermectin
(meta)
Zinc
(meta)
Lactoferrin
(meta)
Other Treatments
Global Adoption
Outcomes in COVID-19 nitazoxanide studies
Home
Share
Tweet
Studies
Studies
Global Adoption
Adoption
Submit Feedback
Feedback
Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Monoclonals..
Bamlanivimab/etesevimab
Bebtelovimab
Casirivimab/imdevimab
Sotrovimab
Tixagevimab/cilgavimab
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Vitamin A
Vitamin C
Vitamin D
Zinc
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes
0
0.5
1
1.5+
All studies
36%
12
3,530
Improvement, Studies, Patients
Relative Risk
Mortality
42%
6
1,877
Ventilation
82%
3
588
ICU admission
28%
3
841
Hospitalization
61%
6
1,864
Recovery
5%
4
1,233
Cases
17%
1
505
Viral clearance
52%
6
790
RCTs
9%
9
2,879
RCT mortality
28%
4
1,339
Peer-reviewed
58%
9
2,532
Prophylaxis
66%
1
505
Early
33%
7
2,469
Late
12%
4
556
Nitazoxanide for COVID-19
c19nitazoxanide.com Aug 2022
Favors
nitazoxanide
Favors
control
after exclusions
0
0.5
1
1.5+
ALL STUDIES
MORTALITY
VENTILATION
ICU ADMISSION
HOSPITALIZATION
RECOVERY
CASES
VIRAL CLEARANCE
RANDOMIZED CONTROLLED TRIALS
RCT MORTALITY
PEER-REVIEWED
After Exclusions
ALL STUDIES
All
Prophylaxis
Early
Late
Nitazoxanide for COVID-19
C19NITAZOXANIDE.COM AUG 2022
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI]
Treatment
Control
Cadegiani
88%
0.12 [0.01-2.52]
death
0/357
2/137
Elalfy
87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT
2
Silva (SB RCT)
26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
death
1/184
0/195
ANTICOV (RCT)
-188%
2.88 [1.05-7.85]
progression
15/462
5/443
OT
1
CT
2
Medhat (RCT)
56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Tau
2
= 1.12, I
2
= 80.8%, p = 0.43
Early treatment
33%
0.67 [0.25-1.78]
25/1,359
51/1,110
33% improvement
Blum (DB RCT)
67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI]
Treatment
Control
Calderón
68%
0.32 [0.04-2.49]
death
1/17
5/27
OT
1
Fowotade (RCT)
-11%
1.11 [0.61-2.03]
no recov.
31 (n)
26 (n)
CT
2
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
death
6/202
5/203
Tau
2
= 0.03, I
2
= 7.9%, p = 0.65
Late treatment
12%
0.88 [0.52-1.50]
9/275
16/281
12% improvement
Sokhela (RCT)
66%
0.34 [0.01-8.41]
death
0/240
1/265
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.52
Prophylaxis
66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement
All studies
36%
0.64 [0.34-1.22]
34/1,874
68/1,656
36% improvement
12 nitazoxanide COVID-19 studies
c19nitazoxanide.com Aug 2022
Tau
2
= 0.70, I
2
= 71.6%, p = 0.18
Effect extraction pre-specified
(most serious outcome)
1
OT: comparison with other treatment
2
CT: study uses combined treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI]
Treatment
Control
Cadegiani
88%
0.12 [0.01-2.52]
death
0/357
2/137
Elalfy
87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT
2
Silva (SB RCT)
26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
death
1/184
0/195
Medhat (RCT)
56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Tau
2
= 0.71, I
2
= 72.1%, p = 0.091
Early treatment
55%
0.45 [0.18-1.14]
10/897
46/667
55% improvement
Blum (DB RCT)
67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI]
Treatment
Control
Calderón
68%
0.32 [0.04-2.49]
death
1/17
5/27
OT
1
Fowotade (RCT)
-11%
1.11 [0.61-2.03]
no recov.
31 (n)
26 (n)
CT
2
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
death
6/202
5/203
Tau
2
= 0.03, I
2
= 7.9%, p = 0.65
Late treatment
12%
0.88 [0.52-1.50]
9/275
16/281
12% improvement
Sokhela (RCT)
66%
0.34 [0.01-8.41]
death
0/240
1/265
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.52
Prophylaxis
66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement
All studies
47%
0.53 [0.29-0.99]
19/1,412
63/1,213
47% improvement
11 nitazoxanide COVID-19 studies after exclusions
c19nitazoxanide.com Aug 2022
Tau
2
= 0.53, I
2
= 65.4%, p = 0.044
Effect extraction pre-specified
(most serious outcome)
1
OT: comparison with other treatment
2
CT: study uses combined treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani
88%
0.12 [0.01-2.52]
0/357
2/137
Improvement, RR [CI]
Treatment
Control
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
1/184
0/195
Tau
2
= 2.67, I
2
= 51.4%, p = 0.75
Early treatment
41%
0.59 [0.02-13.8]
1/541
2/332
41% improvement
Blum (DB RCT)
67%
0.33 [0.07-1.50]
2/25
6/25
Improvement, RR [CI]
Treatment
Control
Calderón
68%
0.32 [0.04-2.49]
1/17
5/27
OT
1
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
6/202
5/203
Tau
2
= 0.00, I
2
= 0.0%, p = 0.23
Late treatment
40%
0.60 [0.26-1.39]
9/244
16/255
40% improvement
Sokhela (RCT)
66%
0.34 [0.01-8.41]
0/240
1/265
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.52
Prophylaxis
66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement
All studies
42%
0.58 [0.27-1.24]
10/1,025
19/852
42% improvement
6 nitazoxanide COVID-19 mortality results
c19nitazoxanide.com Aug 2022
Tau
2
= 0.00, I
2
= 0.0%, p = 0.16
1
OT: comparison with other treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani
97%
0.03 [0.00-0.51]
0/357
9/137
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.015
Early treatment
97%
0.03 [0.00-0.51]
0/357
9/137
97% improvement
Blum (DB RCT)
62%
0.38 [0.11-1.25]
3/25
8/25
Improvement, RR [CI]
Treatment
Control
Calderón
87%
0.13 [0.01-2.33]
0/17
4/27
OT
1
Tau
2
= 0.00, I
2
= 0.0%, p = 0.044
Late treatment
68%
0.32 [0.11-0.97]
3/42
12/52
68% improvement
All studies
82%
0.18 [0.04-0.76]
3/399
21/189
82% improvement
3 nitazoxanide COVID-19 mechanical ventilation results
c19nitazoxanide.com Aug 2022
Tau
2
= 0.50, I
2
= 27.5%, p = 0.019
1
OT: comparison with other treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-404%
5.04 [0.24-104]
2/194
0/198
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.3
Early treatment
-404%
5.04 [0.24-104]
2/194
0/198
-404% improvement
Calderón
59%
0.41 [0.25-0.59]
0/17
16/27
OT
1
Improvement, RR [CI]
Treatment
Control
Rocco (DB RCT)
31%
0.69 [0.40-1.17]
20/202
30/203
Tau
2
= 0.00, I
2
= 0.0%, p = 0.15
Late treatment
32%
0.68 [0.40-1.15]
20/219
46/230
32% improvement
All studies
28%
0.72 [0.43-1.21]
22/413
46/428
28% improvement
3 nitazoxanide COVID-19 ICU results
c19nitazoxanide.com Aug 2022
Tau
2
= 0.00, I
2
= 0.0%, p = 0.22
1
OT: comparison with other treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-2%
1.02 [0.30-3.47]
hosp.
5/194
5/198
Improvement, RR [CI]
Treatment
Control
Cadegiani
99%
0.01 [0.00-0.17]
hosp.
0/357
27/137
Rossignol (DB RCT)
79%
0.21 [0.02-1.80]
hosp.
1/184
5/195
Tau
2
= 3.68, I
2
= 78.4%, p = 0.16
Early treatment
83%
0.17 [0.01-2.00]
6/735
37/530
83% improvement
Blum (DB RCT)
56%
0.44 [0.22-0.89]
hosp. time
25 (n)
25 (n)
Improvement, RR [CI]
Treatment
Control
Calderón
52%
0.48 [0.29-0.82]
hosp. time
17 (n)
27 (n)
OT
1
Tau
2
= 0.00, I
2
= 0.0%, p = 0.0004
Late treatment
53%
0.47 [0.31-0.71]
0/42
0/52
53% improvement
Sokhela (RCT)
79%
0.21 [0.01-4.31]
hosp.
0/240
2/265
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.31
Prophylaxis
79%
0.21 [0.01-4.31]
0/240
2/265
79% improvement
All studies
61%
0.39 [0.20-0.78]
6/1,017
39/847
61% improvement
6 nitazoxanide COVID-19 hospitalization results
c19nitazoxanide.com Aug 2022
Tau
2
= 0.29, I
2
= 47.9%, p = 0.0078
1
OT: comparison with other treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI]
Treatment
Control
Cadegiani
88%
0.12 [0.01-2.52]
death
0/357
2/137
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
death
1/184
0/195
ANTICOV (RCT)
-188%
2.88 [1.05-7.85]
progression
15/462
5/443
OT
1
CT
2
Tau
2
= 0.54, I
2
= 26.7%, p = 0.32
Early treatment
-95%
1.95 [0.53-7.22]
18/1,197
7/973
-95% improvement
Blum (DB RCT)
67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI]
Treatment
Control
Calderón
68%
0.32 [0.04-2.49]
death
1/17
5/27
OT
1
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
death
6/202
5/203
Tau
2
= 0.00, I
2
= 0.0%, p = 0.23
Late treatment
40%
0.60 [0.26-1.39]
9/244
16/255
40% improvement
Sokhela (RCT)
66%
0.34 [0.01-8.41]
death
0/240
1/265
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.52
Prophylaxis
66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement
All studies
8%
0.92 [0.39-2.16]
27/1,681
24/1,493
8% improvement
8 nitazoxanide COVID-19 serious outcomes
c19nitazoxanide.com Aug 2022
Tau
2
= 0.51, I
2
= 37.8%, p = 0.86
Effect extraction pre-specified
(most serious outcome)
1
OT: comparison with other treatment
2
CT: study uses combined treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-16%
1.16 [0.84-1.59]
no recov.
59/194
52/198
Improvement, RR [CI]
Treatment
Control
Rossignol (DB RCT)
-7%
1.07 [0.46-2.49]
recov. time
184 (n)
195 (n)
Tau
2
= 0.00, I
2
= 0.0%, p = 0.37
Early treatment
-15%
1.15 [0.85-1.54]
59/378
52/393
-15% improvement
Fowotade (RCT)
-11%
1.11 [0.61-2.03]
no recov.
31 (n)
26 (n)
CT
1
Improvement, RR [CI]
Treatment
Control
Rocco (DB RCT)
27%
0.73 [0.58-0.90]
no disch.
202 (n)
203 (n)
Tau
2
= 0.04, I
2
= 45.6%, p = 0.33
Late treatment
17%
0.83 [0.57-1.21]
0/233
0/229
17% improvement
All studies
5%
0.95 [0.70-1.28]
59/611
52/622
5% improvement
4 nitazoxanide COVID-19 recovery results
c19nitazoxanide.com Aug 2022
Tau
2
= 0.05, I
2
= 54.8%, p = 0.75
1
CT: study uses combined treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Sokhela (RCT)
17%
0.83 [0.50-1.40]
symp. case
23/240
37/265
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.47
Prophylaxis
17%
0.83 [0.50-1.40]
23/240
37/265
17% improvement
All studies
17%
0.83 [0.51-1.36]
23/240
37/265
17% improvement
1 nitazoxanide COVID-19 case result
c19nitazoxanide.com Aug 2022
Tau
2
= 0.00, I
2
= 0.0%, p = 0.47
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
12%
0.88 [0.80-0.96]
viral+
194 (n)
198 (n)
Improvement, RR [CI]
Treatment
Control
Elalfy
87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT
1
Silva (SB RCT)
26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Medhat (RCT)
56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Tau
2
= 0.58, I
2
= 90.3%, p = 0.055
Early treatment
54%
0.46 [0.21-1.02]
7/356
44/335
54% improvement
Blum (DB RCT)
90%
0.10 [0.01-1.78]
viral+
0/23
4/19
Improvement, RR [CI]
Treatment
Control
Fowotade (RCT)
5%
0.95 [0.34-2.64]
viral load
31 (n)
26 (n)
CT
1
Tau
2
= 1.31, I
2
= 52.6%, p = 0.48
Late treatment
53%
0.47 [0.06-3.59]
0/54
4/45
53% improvement
All studies
52%
0.48 [0.25-0.94]
7/410
48/380
52% improvement
6 nitazoxanide COVID-19 viral clearance results
c19nitazoxanide.com Aug 2022
Tau
2
= 0.49, I
2
= 84.9%, p = 0.032
1
CT: study uses combined treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI]
Treatment
Control
Silva (SB RCT)
26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
death
1/184
0/195
ANTICOV (RCT)
-188%
2.88 [1.05-7.85]
progression
15/462
5/443
OT
1
CT
2
Medhat (RCT)
56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Tau
2
= 0.50, I
2
= 64.3%, p = 0.84
Early treatment
-10%
1.10 [0.47-2.59]
18/940
5/922
-10% improvement
Blum (DB RCT)
67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI]
Treatment
Control
Fowotade (RCT)
-11%
1.11 [0.61-2.03]
no recov.
31 (n)
26 (n)
CT
2
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
death
6/202
5/203
Tau
2
= 0.03, I
2
= 8.5%, p = 0.86
Late treatment
5%
0.95 [0.55-1.63]
8/258
11/254
5% improvement
Sokhela (RCT)
66%
0.34 [0.01-8.41]
death
0/240
1/265
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.52
Prophylaxis
66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement
All studies
9%
0.91 [0.56-1.48]
26/1,438
17/1,441
9% improvement
9 nitazoxanide COVID-19 Randomized Controlled Trials
c19nitazoxanide.com Aug 2022
Tau
2
= 0.20, I
2
= 42.8%, p = 0.72
Effect extraction pre-specified
(most serious outcome)
1
OT: comparison with other treatment
2
CT: study uses combined treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
1/184
0/195
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.5
Early treatment
-206%
3.06 [0.13-74.6]
1/184
0/195
-206% improvement
Blum (DB RCT)
67%
0.33 [0.07-1.50]
2/25
6/25
Improvement, RR [CI]
Treatment
Control
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
6/202
5/203
Tau
2
= 0.19, I
2
= 28.2%, p = 0.46
Late treatment
35%
0.65 [0.22-1.98]
8/227
11/228
35% improvement
Sokhela (RCT)
66%
0.34 [0.01-8.41]
0/240
1/265
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.52
Prophylaxis
66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement
All studies
28%
0.72 [0.31-1.70]
9/651
12/688
28% improvement
4 nitazoxanide COVID-19 RCT mortality results
c19nitazoxanide.com Aug 2022
Tau
2
= 0.00, I
2
= 0.0%, p = 0.46
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI]
Treatment
Control
Cadegiani
88%
0.12 [0.01-2.52]
death
0/357
2/137
Elalfy
87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT
2
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
death
1/184
0/195
Medhat (RCT)
56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Tau
2
= 0.84, I
2
= 67.1%, p = 0.11
Early treatment
61%
0.39 [0.13-1.23]
10/874
46/654
61% improvement
Blum (DB RCT)
67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI]
Treatment
Control
Calderón
68%
0.32 [0.04-2.49]
death
1/17
5/27
OT
1
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
death
6/202
5/203
Tau
2
= 0.00, I
2
= 0.0%, p = 0.23
Late treatment
40%
0.60 [0.26-1.39]
9/244
16/255
40% improvement
Sokhela (RCT)
66%
0.34 [0.01-8.41]
death
0/240
1/265
Improvement, RR [CI]
Treatment
Control
Tau
2
= 0.00, I
2
= 0.0%, p = 0.52
Prophylaxis
66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement
All studies
58%
0.42 [0.20-0.86]
19/1,358
63/1,174
58% improvement
9 nitazoxanide COVID-19 peer reviewed trials
c19nitazoxanide.com Aug 2022
Tau
2
= 0.50, I
2
= 51.4%, p = 0.018
Effect extraction pre-specified
(most serious outcome)
1
OT: comparison with other treatment
2
CT: study uses combined treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI]
Treatment
Control
Rocco (RCT)
-2%
1.02 [0.30-3.47]
hosp.
5/194
5/198
Rocco (RCT)
-16%
1.16 [0.84-1.59]
no recov.
59/194
52/198
Rocco (RCT)
12%
0.88 [0.80-0.96]
viral+
194 (n)
198 (n)
Rocco (RCT)
14%
0.86 [0.77-0.96]
viral+
136/194
162/198
Cadegiani
88%
0.12 [0.01-2.52]
death
0/357
2/137
Cadegiani
97%
0.03 [0.00-0.51]
ventilation
0/357
9/137
Cadegiani
99%
0.01 [0.00-0.17]
hosp.
0/357
27/137
Elalfy
87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT
2
Elalfy
58%
0.42 [0.31-0.56]
viral+
26/62
51/51
CT
2
Silva (SB RCT)
26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Silva (SB RCT)
38%
0.62 [0.39-0.97]
viral+
12/23
11/13
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
death
1/184
0/195
Rossignol (DB RCT)
79%
0.21 [0.02-1.80]
hosp.
1/184
5/195
Rossignol (DB RCT)
85%
0.15 [0.02-1.22]
severe case
1/184
7/195
Rossignol (DB RCT)
84%
0.16 [0.02-1.29]
severe case
1/112
7/126
Rossignol (DB RCT)
-7%
1.07 [0.46-2.49]
recov. time
184 (n)
195 (n)
ANTICOV (RCT)
-188%
2.88 [1.05-7.85]
progression
15/462
5/443
OT
1
CT
2
Medhat (RCT)
56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Blum (DB RCT)
67%
0.33 [0.07-1.50]
death
2/25
6/25
Blum (DB RCT)
62%
0.38 [0.11-1.25]
ventilation
3/25
8/25
Blum (DB RCT)
56%
0.44 [0.22-0.89]
hosp. time
25 (n)
25 (n)
Blum (DB RCT)
90%
0.10 [0.01-1.78]
viral+
0/23
4/19
Calderón
68%
0.32 [0.04-2.49]
death
1/17
5/27
OT
1
Calderón
87%
0.13 [0.01-2.33]
ventilation
0/17
4/27
OT
1
Calderón
59%
0.41 [0.25-0.59]
ICU
0/17
16/27
OT
1
Calderón
52%
0.48 [0.29-0.82]
hosp. time
17 (n)
27 (n)
OT
1
Fowotade (RCT)
-11%
1.11 [0.61-2.03]
no recov.
31 (n)
26 (n)
CT
2
Fowotade (RCT)
-87%
1.87 [0.88-3.98]
no recov.
31 (n)
26 (n)
CT
2
Fowotade (RCT)
5%
0.95 [0.34-2.64]
viral load
31 (n)
26 (n)
CT
2
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
death
6/202
5/203
Rocco (DB RCT)
<